Literature DB >> 18607871

Fracture risk in patients with different types of cancer.

Peter Vestergaard1, Lars Rejnmark, Leif Mosekilde.   

Abstract

BACKGROUND: Few studies on the risk of fractures in patients with cancer exist, and little is known on the mechanisms of fractures in patients with cancer. We studied the risk of fracture in patients with various types of cancer. SUBJECTS AND METHODS: Case control study. There were 124,655 fracture cases and 373,962 age and gender matched controls.
RESULTS: An increased risk of fractures, primarily within the first year after diagnosis was seen in patients with primary bone cancer (OR=3.51, 95% CI: 1.54-8.01), multiple myeloma (OR=5.21, 95% CI: 2.96-9.19), metastases to the bone (OR=5.28, 95% CI: 3.58-7.79), metastases to other organs than bone (OR=1.85, 95% CI: 1.50-2.29), lung cancer (OR=1.90, 95% CI: 1.51-2.38), and cancer of the liver, gall bladder and pancreas (2.14, 95% CI: 1.39-3.31). For patients with prostate cancer an increase in the risk of fractures was seen with time. Other cancer types were not associated with an increased risk of fractures.
CONCLUSIONS: A high risk group regarding fractures includes cancers primarily affecting the bone (primary bone cancer, multiple myeloma, metastases to the bone, metastases to other organs than bone, lung cancer, and cancer of the liver, gall bladder and pancreas, and prostate cancer). The main increase in risk of fractures in this group was seen within the first year following diagnosis. A low risk group for fractures included all other cancer types (e.g. cancer of the breast, colon, skin etc). This may have implication for which patients should be selected for prevention against fractures.

Entities:  

Mesh:

Year:  2009        PMID: 18607871     DOI: 10.1080/02841860802167490

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

Review 1.  Evaluation and management of skeletal disease in cancer care.

Authors:  Anuhya Kommalapati; Sri Harsha Tella; Mary Angelynne Esquivel; Ricardo Correa
Journal:  Crit Rev Oncol Hematol       Date:  2017-09-08       Impact factor: 6.312

2.  Fracture risk in women with breast cancer: a population-based study.

Authors:  L Joseph Melton; Lynn C Hartmann; Sara J Achenbach; Elizabeth J Atkinson; Terry M Therneau; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

3.  Evaluating the performance of the Charlson Comorbidity Index (CCI) in fracture risk prediction and developing a new Charlson Fracture Index (CFI): a register-based cohort study.

Authors:  A Clausen; S Möller; M K Skjødt; B H Bech; K H Rubin
Journal:  Osteoporos Int       Date:  2022-01-06       Impact factor: 4.507

4.  Screening recall in older cancer survivors detects differences in balance and mobility.

Authors:  Jennifer Blackwood; Robert Sweeney; Kateri Rybicki
Journal:  Support Care Cancer       Date:  2021-11-23       Impact factor: 3.603

Review 5.  Osteoporosis in Skin Diseases.

Authors:  Maria Maddalena Sirufo; Francesca De Pietro; Enrica Maria Bassino; Lia Ginaldi; Massimo De Martinis
Journal:  Int J Mol Sci       Date:  2020-07-03       Impact factor: 5.923

6.  Osteoporotic fracture rates in chronic hemodialysis and effect of heparin exposure: a retrospective cohort study.

Authors:  Hind Harrak; Emilie René; Noor Alsalemi; Naoual Elftouh; Jean-Philippe Lafrance
Journal:  BMC Nephrol       Date:  2020-07-09       Impact factor: 2.388

7.  PATHOLOGICAL FRACTURES DUE TO BONE METASTASES FROM LUNG CANCER: RISK FACTORS AND SURVIVAL.

Authors:  Marcelo Bragança Dos Reis Oliveira; Bruno de Carvalho Marques; Rosa Aurílio Matos; César Rubens da Costa Fontenelle; Fernanda Carvalho de Queiroz Mello; Marcos Eduardo Machado Paschoal
Journal:  Acta Ortop Bras       Date:  2018       Impact factor: 0.513

Review 8.  Incorporating clinical trial data into daily cancer care.

Authors:  Jody Pelusi
Journal:  J Adv Pract Oncol       Date:  2012-11

9.  Breast cancer survivors are at an increased risk for osteoporotic fractures not explained by lower BMD: a retrospective analysis.

Authors:  Merav Fraenkel; David B Geffen; Victor Novack; Tali Shafat; Yuval Mizrakli; Samuell Ariad; Michael Koretz; Larry Norton; Ethel Siris
Journal:  NPJ Breast Cancer       Date:  2015-07-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.